DAX19.323 +0,9%ESt504.789 +0,7%MSCIW3.773 +0,2%Dow44.297 +1,0%Nas19.004 +0,2%Bitcoin93.893 +0,5%Euro1,0484 +0,6%Öl74,62 -0,9%Gold2.666 -1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 Deutsche Telekom 555750 BASF BASF11 Amazon 906866 Allianz 840400 Palantir A2QA4J Novo Nordisk A3EU6F Apple 865985
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen uneinheitlich -- RENK bekommt neue Führungsspitze -- VW hält an Werksschließungen fest -- thyssenkrupp Steel offenbar mit Finanzierungszusage -- Daimler Truck im Fokus
Top News
Steigern Sie Ihre Zinsen mit gezieltem Zinshopping Steigern Sie Ihre Zinsen mit gezieltem Zinshopping
General Motors-Aktie: Einstieg von Cadillac in Formel 1? General Motors-Aktie: Einstieg von Cadillac in Formel 1?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Gensight Biologics SA Aktie

NeuKaufenVerkaufen
0,3110 EUR -3,2630 EUR -91,30 %
STU
0,3150 EUR -0,0035 EUR -1,10 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.36,28 Mio. EUR

Div. Rendite0,00%

WKNA2ANGZ

ISINFR0013183985

SymbolGSGTF

Gensight Biologics SA Aktien News

DatumMeistgelesen
BusinesswireGenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
BusinesswireGenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
BusinesswireGenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
Wer­bungGensight Biologics SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireGenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
BusinesswireGenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
BusinesswireGenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
BusinesswireGenSight Biologics Launches Newsletter for Retail Investors
BusinesswireGenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
BusinesswireGenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
BusinesswireGenSight Biologics Appoints William Monteith to its Board of Directors
BusinesswireGenSight Biologics Announces the Filing of its 2023 Universal Registration Document
BusinesswireGenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
BusinesswireGenSight Biologics Announces its 2024 Financial Calendar
BusinesswireGenSight Biologics Reports Full Year 2023 Consolidated Financial Results
BusinesswireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
BusinesswireGenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
BusinesswireGenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
BusinesswireGenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
BusinesswireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
BusinesswireGenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
BusinesswireGenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
BusinesswireGenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
BusinesswireGenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
BusinesswireGenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
BusinesswireGenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
BusinesswireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
BusinesswireGenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
BusinesswireGenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

Gensight Biologics SA News

Gensight Biologics SA News: auf dieser Seite finden Sie alle Gensight Biologics SA News und Nachrichten zur Gensight Biologics SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gensight Biologics SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Gensight Biologics SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.